Venture Life buys FemiClear and CUROXEN, names U.S. leader

Venture Life Group acquired the FemiClear and CUROXEN brands and appointed Janet Carter Smith to run Venture Life USA, marking a bigger push into the U.S. self-care market. The deal gives the UK company a broader retail platform in women’s intimate health and sets up synergies expected to start flowing from 2027.

Why it matters: - Venture Life is building a bigger U.S. platform in one of the world’s largest self-care markets. - The acquisition adds immediate scale in women’s intimate health and creates a base for expanding more of Venture Life’s portfolio in the U.S. - The deal also brings retailer relationships, intellectual property and an experienced team that can support future growth.

What happened: - Venture Life Group plc acquired the FemiClear and CUROXEN brands from OrganiCare Nature’s Sciences, LLC. - Venture Life also appointed Janet Carter Smith as Commercial General Manager, Venture Life USA. - The announcement was made on August 13, 2026. - Venture Life said the acquisition and appointment are its biggest step yet into the United States.

The details: - FemiClear targets bacterial vaginosis, genital herpes, yeast infections, urinary tract infections and broader vaginal health. - CUROXEN offers infection protection solutions for wounds and mouth sores. - The brands are sold in the U.S. through Walmart, Walgreens, CVS and Target. - FemiClear is the larger brand and is the No. 1 natural brand in the U.S. FemCare market. - Six members of the OrganiCare team will join Venture Life. - Venture Life said the team will help build an owned U.S. commercial platform that can also support the wider group portfolio. - The acquisition expands Venture Life’s presence in women’s intimate health and adds adjacent treatment categories. - The deal complements Balance Activ and creates access to a stated $0.7 billion U.S. feminine treatment retail opportunity. - Venture Life expects revenue and operational synergies from using existing distribution relationships, cross-applying expertise, sharing intellectual property and product development capabilities, and improving operational and technology efficiency. - Venture Life expects those benefits to phase in from calendar year 2027 onward. - Janet Carter Smith has experience across natural health, retail strategy and brand building, including direct experience with FemiClear and CUROXEN. - Venture Life USA plans to consolidate its current U.S. presence and then introduce more of the group’s global portfolio. - Venture Life said Health & Her is already gaining retail traction at CVS. - Venture Life also highlighted Lift, a 15g glucose shot aimed at Americans managing diabetes. - Jerry Randall said the acquisition is margin enhancing and comes with significant confirmed new listings landing through 2026 that will fully impact in 2027. - Janet Carter Smith said Venture Life USA aims to become a leading consumer self care company and a category growth partner for retailers.

Between the lines: - The acquisition gives Venture Life a ready-made U.S. commercial footprint instead of starting from scratch. - Adding a dedicated U.S. general manager suggests the company wants tighter local execution and faster retail expansion. - The focus on science-backed brands and major retailers points to a strategy built around credibility, distribution and category growth rather than a single-brand play.

What's next: - Venture Life will fold the acquired brands and team into Venture Life USA. - The company will use the U.S. platform to push FemiClear, CUROXEN, Health & Her and Lift into more stores. - Expected synergies and new listings are set to begin showing up more fully in 2027. - Venture Life will also look to extend its broader self-care portfolio in the U.S. retail market.

The bottom line: - Venture Life is turning its U.S. push into a platform strategy, not just a brand acquisition.